Dr. Martens PLC
07 October 2026
7 October 2026
DR. MARTENS PLC ("the Company" and, together with its subsidiaries, "the Group")
Group Reporting Changes and Re-presentation of Historical Financial Data
In our FY26 results on 19 May 2026, we announced that in FY27 we would move to market-based reporting, and no longer report on a regional basis, in line with the new operating model for the business. To aid investor understanding, we are today publishing historical financial data in the new reporting structure.
Change in reportable segments
The Group has revised its reportable segments under IFRS 8 'Operating Segments' to better reflect the way the management team reviews performance, allocates resources and executes the strategy.
Effective from 1 April 2026, the Group now has two reportable segments: (1) "US" and, (2) "Global Markets (ex US)". Corporate overhead and functional costs are not allocated to these two segments and are presented separately within "Central" as an unallocated reconciling item.
Impact and re-presentation of financial data
To facilitate meaningful comparison with future reporting periods, historical comparative information has been re-presented to reflect this revised reporting structure.
The re-presentation affects only the allocation and presentation of financial information between the Group's reportable segments and unallocated Central costs. It has no impact on the Group's previously reported consolidated revenue, gross margin, profit before tax, consolidated statement of financial position or earnings per share (EPS).
From a channel perspective, we will disclose DTC:B2B revenue mix at a Group level. We are also enhancing our disclosure to include Demand Generating Spend at a Group level going forward, to aid understanding of operating costs (historic figures are included in the table below).
FY25 and FY26 re-presented historical information
|
H1 FY26 |
|
H2 FY26 |
|
FY26 |
|||||||||||
|
|
US |
Global Markets |
Central |
Total |
|
US |
Global Markets |
Central |
Total |
|
US |
Global Markets |
Central |
Total |
|
|
£m |
£m |
£m |
£m |
|
£m |
£m |
£m |
£m |
|
£m |
£m |
£m |
£m |
||
|
Revenue |
107.6 |
214.4 |
- |
322.0 |
|
151.0 |
291.9 |
- |
442.9 |
|
258.6 |
506.3 |
- |
764.9 |
|
|
Gross margin |
62.7 |
147.6 |
- |
210.3 |
|
95.4 |
200.3 |
- |
295.7 |
|
158.1 |
347.9 |
- |
506.0 |
|
|
Adjusted EBIT |
16.8 |
61.7 |
(75.4) |
3.1 |
|
43.7 |
100.8 |
(68.3) |
76.2 |
|
60.5 |
162.5 |
(143.7) |
79.3 |
|
|
EBIT |
15.8 |
61.2 |
(75.5) |
1.5 |
|
43.3 |
98.5 |
(86.3) |
55.5 |
|
59.1 |
159.7 |
(161.8) |
57.0 |
|
|
Adjusted profit/(Loss) before tax |
15.8 |
60.2 |
(85.4) |
(9.4) |
|
42.6 |
99.4 |
(77.6) |
64.4 |
|
58.4 |
159.6 |
(163.0) |
55.0 |
|
|
Profit/(Loss) before tax |
14.8 |
59.7 |
(85.5) |
(11.0) |
|
42.2 |
97.1 |
(95.6) |
43.7 |
|
57.0 |
156.8 |
(181.1) |
32.7 |
|
|
|
|||||||||||||||
|
Demand generating spend |
|
|
|
(22.4) |
|
|
|
|
(33.9) |
|
|
|
|
(56.3) |
|
|
H1 FY25 |
|
H2 FY25 |
|
FY25 |
|||||||||||
|
|
US |
Global Markets |
Central |
Total |
|
US |
Global Markets |
Central |
Total |
|
US |
Global Markets |
Central |
Total |
|
|
£m |
£m |
£m |
£m |
|
£m |
£m |
£m |
£m |
|
£m |
£m |
£m |
£m |
||
|
Revenue |
106.2 |
218.4 |
- |
324.6 |
|
164.1 |
298.9 |
- |
463.0 |
|
270.3 |
517.3 |
- |
787.6 |
|
|
Gross margin |
63.1 |
144.6 |
- |
207.7 |
|
96.8 |
207.2 |
- |
304.0 |
|
159.9 |
351.8 |
- |
511.7 |
|
|
Adjusted EBIT |
13.6 |
58.4 |
(75.0) |
(3.0) |
|
41.0 |
101.1 |
(78.4) |
63.7 |
|
54.6 |
159.5 |
(153.4) |
60.7 |
|
|
EBIT |
12.3 |
58.4 |
(85.8) |
(15.1) |
|
40.2 |
98.9 |
(87.0) |
52.1 |
|
52.5 |
157.3 |
(172.8) |
37.0 |
|
|
Adjusted Profit/(Loss) before tax |
12.5 |
56.8 |
(85.9) |
(16.6) |
|
40.0 |
99.5 |
(88.8) |
50.7 |
|
52.5 |
156.3 |
(174.7) |
34.1 |
|
|
Profit/(Loss) before tax |
11.2 |
56.8 |
(96.7) |
(28.7) |
|
39.2 |
97.3 |
(99.0) |
37.5 |
|
50.4 |
154.1 |
(195.7) |
8.8 |
|
|
Demand generating spend |
|
|
|
(20.0) |
|
|
|
|
(36.5) |
|
|
|
|
(56.5) |
|
|
FY26 |
|
FY25 |
||||||
|
Revenue by market £m |
|
H1 |
H2 |
FY26 |
|
H1 |
H2 |
FY25 |
|
US |
107.6 |
151.0 |
258.6 |
|
106.2 |
164.1 |
270.3 |
|
|
Global Markets (ex US) |
214.4 |
291.9 |
506.3 |
|
218.4 |
298.9 |
517.3 |
|
|
UK |
|
53.4 |
82.1 |
135.5 |
|
56.3 |
85.8 |
142.1 |
|
DACH |
|
34.3 |
53.2 |
87.5 |
|
35.2 |
51.4 |
86.6 |
|
Japan |
|
20.2 |
26.9 |
47.1 |
|
20.2 |
29.5 |
49.7 |
|
Other Managed Markets |
|
90.7 |
116.6 |
207.3 |
|
90.1 |
120.0 |
210.1 |
|
Partner Markets |
|
15.8 |
13.1 |
28.9 |
|
16.6 |
12.2 |
28.8 |
|
Total |
322.0 |
442.9 |
764.9 |
|
324.6 |
463.0 |
787.6 |
|
Other reporting changes
The Group has re-categorised Mules from Sandals to Shoes, which will have the impact of reducing the previously disclosed Sandals revenue. The impact on FY26 is c.4%pts shift in revenue mix from sandals into shoes.
Ends
Investors and analysts:
Bethany Barnes, Director of Investor Relations & Corporate Communications
+44782187465
Press enquiries:
Rob Greening / Ludo Baynham-Herd / Oliver Banks
drmartens@client.sodali.com
+44 207 250 1446
Notes to editors
ABOUT DR. MARTENS
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1 April 1960. Stitched into its heel loop were three words in the founder's own handwriting, a nod to the boot's new air-cushioned sole: With Bouncing Soles. Originally chosen by workers for their comfort and durability, "Doc's" or "DM's" boots and shoes were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.
Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.
Those same three words are now the brand's enduring global platform. With Bouncing Soles is not a tagline or a seasonal campaign; it is a statement of intent and a creative thread that runs through everything Dr. Martens does, from product and retail to partnerships and community. What began as a promise of comfort has become an opportunity for reflection and a call to action: What Makes Your Sole Bounce?
It celebrates the individuality, creativity and self-expression of a global community glorious in its differences, united by a yellow thread.
A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections span its original silhouettes, including The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot and Adrian loafer, as well as newer franchises including the Zebzag, Buzz and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories. Every Dr. Martens collection reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand remains as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.
Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.
For more information, visitwww.drmartens.comorhttp://www.drmartensplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.